» Articles » PMID: 34498295

The Biochemical Diagnosis of Adrenal Insufficiency with Modern Cortisol Assays: Reappraisal in the Setting of Opioid Exposure and Hospitalization

Overview
Specialty Endocrinology
Date 2021 Sep 9
PMID 34498295
Citations 3
Authors
Affiliations
Soon will be listed here.
Abstract

Objective: We aimed to (1) examine the diagnosis of opioid-induced adrenal insufficiency, and (2) investigate the diagnostic value of a morning cortisol <83 nmol/L (3 µg/dl) for the diagnosis of adrenal insufficiency, using newer more specific cortisol assays and cut-offs.

Design: Retrospective study (5/2015-10/2020).

Participants: Cohort 1 (N = 75): adults who underwent cosyntropin stimulation testing and opioid exposure for >30 days. Cohort 2 (N = 854): adults, with or without opioid exposure, who had a morning cortisol level measured the same day as stimulation testing.

Measurements: Peak cortisol during cosyntropin stimulation testing. Sensitivity and specificity of morning serum cortisol for adrenal insufficiency.

Results: The prevalence of adrenal insufficiency in patients with chronic opioid exposure who underwent cosyntropin stimulation testing was 4.0% using a cortisol cutoff of <405 nmol/L (14.7 µg/dl) versus 19% using the traditional cutoff of <500 nmol/L (18.1 µg/dl). For hospitalized patients with and without opioid-exposure, 14 of 22 (64%) patients with morning cortisol levels of <83 nmol/L (3 µg/dl) passed cosyntropin stimulation testing. A morning cortisol level of <348 nmol/L (12.6 µg/dl) had 100% sensitivity (95% confidence interval: 84.5%-100%) for the diagnosis of adrenal insufficiency.

Conclusion: Applying a cutoff of <405 nmol/L (14.7 µg/dl), opioid-induced adrenal insufficiency is rare. Nearly 1 out of 6 patients would be reclassified as having adrenal insufficiency applying the guideline-recommended cutoff of <500 nmol/L (18.1 µg/dl). Serum morning cortisol <83 nmol/L (3 µg/dl) is not a valid diagnostic test for adrenal insufficiency in hospitalized patients, whether or not receiving opioids.

Citing Articles

Opioid-induced adrenal insufficiency: diagnostic and management considerations.

Patel E, Ben-Shlomo A Front Endocrinol (Lausanne). 2024; 14:1280603.

PMID: 38476510 PMC: 10927719. DOI: 10.3389/fendo.2023.1280603.


A Closer Look at Opioid-Induced Adrenal Insufficiency: A Narrative Review.

Coluzzi F, LeQuang J, Sciacchitano S, Scerpa M, Rocco M, Pergolizzi J Int J Mol Sci. 2023; 24(5).

PMID: 36902007 PMC: 10003084. DOI: 10.3390/ijms24054575.


Advanced Adrenocortical Carcinoma: From Symptoms Control to Palliative Care.

Ruggiero E, Tizianel I, Caccese M, Lombardi G, Pambuku A, Zagonel V Cancers (Basel). 2022; 14(23).

PMID: 36497381 PMC: 9739560. DOI: 10.3390/cancers14235901.